Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

NCT06094868 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Fruquintinib

Sponsor

Second Affiliated Hospital of Nanchang University